Generali Investments CEE investicni spolecnost a.s. Acquires New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Generali Investments CEE investicni spolecnost a.s. acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 6,100 shares of the medical equipment provider's stock, valued at approximately $644,000.

Several other large investors also recently added to or reduced their stakes in the business. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Dunhill Financial LLC raised its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the third quarter valued at approximately $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $35,000. Finally, Kentucky Trust Co bought a new position in shares of Zimmer Biomet in the 4th quarter worth $39,000. Institutional investors own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research analyst reports. JMP Securities reaffirmed a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Truist Financial restated a "hold" rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus target price of $124.15.

Remove Ads

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.95% of the company's stock.

Zimmer Biomet Trading Down 3.0 %

ZBH traded down $3.24 during midday trading on Wednesday, reaching $104.10. 2,123,682 shares of the company's stock traded hands, compared to its average volume of 1,914,477. The stock has a market capitalization of $20.72 billion, a price-to-earnings ratio of 23.39, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The firm has a fifty day moving average of $105.68 and a two-hundred day moving average of $107.08. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company earned $2.20 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet's dividend payout ratio (DPR) is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.